Cas:517-09-9 equilenin manufacturer & supplier

We serve Chemical Name:equilenin CAS:517-09-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

equilenin

Chemical Name:equilenin
CAS.NO:517-09-9
Synonyms:Equilenin solution;EQU;Equilenina;d-Equilenin
Molecular Formula:C18H18O2
Molecular Weight:266.33400
HS Code:

Physical and Chemical Properties:
Melting point:258-259°
Boiling point:472.6ºC at 760mmHg
Density:1.242g/cm3
Index of Refraction:1.662
PSA:37.30000
Exact Mass:266.13100
LogP:3.94440

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 1648 3/PG 2
Packing Group:


Contact us for information like Equilenin solution chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,d-Equilenin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Equilenina Use and application,EQU technical grade,usp/ep/jp grade.


Related News: An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D. equilenin manufacturer Last year, California became the first state in the country to ban toxic chemicals in cosmetics — including a number of PFAS. Maryland did the same this month, but the laws don’t take effect until 2025, the Post reported. equilenin supplier For both Black and white women, younger age and ER-negative breast cancer were risk factors in the genes most strongly associated with breast cancer, including BRCA1, BRCA2 and PALB2. equilenin vendor An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D. equilenin factory An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.